Treatment recommendations for IgA vasculitis (IgAV)-associated nephritis (IgAVN) are mainly based on expert opinion resulting in variation. A recent review describes B-cell depletion as a potential treatment for IgAVN.1 Successful treatment of IgAVN with rituximab has been reported in adult patients.2 To our knowledge, only one case series of three children has reported rituximab treatment for IgAV, and two of them had IgAVN.3

We recently reported on a large international cohort of 1148 children with biopsy-proven IgAVN.4 For this study, we retrospectively analysed all patients who received rituximab.

Eleven patients from nine international centres received rituximab at a median time of 1.5 months (IQR 0.6–2.1) after the onset of IgAV. The median estimated glomerular filtration rate (eGFR) at biopsy was 119.3 mL/min/1.73 m2 (IQR 82.3–147.7). Protein–creatinine ratio (UPUC) >200 mg/mmol was present in nine patients. Eight patients had hypoalbuminaemia (<35 g/L). At the start of rituximab, median eGFR was 88.9 mL/min/1.73 m2 (IQR 58.9–128.5) and median UPUC 837.0 mg/mmol (IQR 421–1420). Patient data including additional treatments are summarised in table 1.

3–6 months after rituximab treatment, the median eGFR was …